Summary

This article discusses a subset analysis of the larger PLATO trial where ticagrelor was superior to clopidogrel in terms of preventing cardiovascular death, myocardial infarction, or stroke in patients who presented with STEMI and for whom PCI was planned, without causing a significant increase in major bleeding.